Company profile
UCB
Immunology + neurology
Share price · UCBJY
$126.00-8.10 (-6.04%) 3M
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(15 total)
15Total Assets
9Approved
1Phase 3 / Filed
5Phase 1–2 / Early
10Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
bimekizumab(Bimzelx) | Approved | IL-17A/FMonoclonal antibody | Psoriatic ArthritisAtopic DermatitisPsoriasis |
| Approved | Synaptic vesicle glycoprotein 2A (SV2A)Small molecule | Epilepsy | |
certolizumab pegol(Cimzia) | Approved | TNF-alphaAntibody fragment | Inflammatory Bowel DiseasePsoriasisRheumatoid Arthritis Crohn's Disease |
| Approved | Serotonin 5-HT2 receptorsSmall molecule | Epilepsy | |
| Approved | Voltage-gated sodium channelSmall molecule | Epilepsy | |
Levetiracetam (Keppra)(Keppra) | Approved | Synaptic vesicle glycoprotein 2A (SV2A)Small molecule | Epilepsy |
Midazolam (Nayzilam)(Nayzilam) | Approved | GABA-A receptor · GABA-A receptor (benzodiazepine site)Small molecule | Epilepsy |
Parcopa(Parcopa) | Approved | dopamine precursorSmall molecule | Parkinson's Disease |
rotigotine(Neupro) | Approved | dopamineSmall molecule | Parkinson's Disease |
| Phase 3 | GABA-A receptorCombination | Epilepsy | |
| Phase 2 | Tau (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease | |
| Phase 2 | IL-13, IL-17A, IL-17FMultispecific antibody | Atopic Dermatitis | |
| Phase 2 | D1 receptorSmall molecule | Parkinson's Disease | |
| Phase 1 | BCMA x CD3Multispecific antibody | AsthmaSystemic Lupus Erythematosus | |
UCB7853No recent activity | Phase 1 | alpha-synucleinBiologic — subtype unspecified | Parkinson's Disease |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Research
Sign in to access ResearchUnlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Research
Sign in to access ResearchUnlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.